Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Mavrilimumab to Reduce Progression of Acute Respiratory Failure in Patients With Severe COVID-19 Pneumonia and Systemic Hyper-inflammation

NCT04399980 is registered in ClinicalTrials.gov with The Cleveland Clinic as lead sponsor.

NCT NCT04399980
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04399980 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Mavrilimumab to Reduce Progression of Acute Respiratory Failure in Patients With Severe COVID-19 Pneumonia and Systemic Hyper-inflammation
Lead sponsor
The Cleveland Clinic
Phase
Phase 2
Overall status
Completed
Start date
May 20, 2020
Completion date
April 23, 2021
Enrollment
40 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

covid 19, pneumonia, sars-cov 2